Correspondence 0001437749-23-019781 from CervoMed Inc. (CRVO)
CervoMed Inc.
Date: July 12, 2023 · CIK: 0001053691 · Accession: 0001437749-23-019781
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271823
Letter
dffn20230712_corresp.htm
DIFFUSION PHARMACEUTICALS INC.
300 East Main Street
Suite 201
Charlottesville, Virginia 22902
July 12, 2023
VIA EDGAR
Suzanne Hayes
Dillon Haigus
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-4
(File No. 333-271823)
Originally filed on May 11, 2023, as amended
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Diffusion Pharmaceuticals Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-4 to become effective on Thursday, July 13, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable.
The Registrant requests that it be notified of such effectiveness by a telephone call to David Rosenthal, Esq. of Dechert LLP, counsel to the Registrant, at (212) 698-3616 or by an email to david.rosenthal@dechert.com.
Thank you for your assistance. If you should have any questions, please contact Mr. Rosenthal at (212) 698-3616.
Very truly yours,
/s/ Robert J. Cobuzzi, Jr., Ph.D.
Show Raw Text
CORRESP 1 filename1.htm dffn20230712_corresp.htm DIFFUSION PHARMACEUTICALS INC. 300 East Main Street Suite 201 Charlottesville, Virginia 22902 July 12, 2023 VIA EDGAR Suzanne Hayes Dillon Haigus Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Diffusion Pharmaceuticals Inc. Registration Statement on Form S-4 (File No. 333-271823) Originally filed on May 11, 2023, as amended Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Diffusion Pharmaceuticals Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-4 to become effective on Thursday, July 13, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable. The Registrant requests that it be notified of such effectiveness by a telephone call to David Rosenthal, Esq. of Dechert LLP, counsel to the Registrant, at (212) 698-3616 or by an email to david.rosenthal@dechert.com. Thank you for your assistance. If you should have any questions, please contact Mr. Rosenthal at (212) 698-3616. Very truly yours, /s/ Robert J. Cobuzzi, Jr., Ph.D. Robert J. Cobuzzi, Jr., Ph.D. President and Chief Executive Officer